Trevi Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Trevi Therapeutics

20/03/2024 21:02

* Trevi Therapeutics Inc  TRVI.OQ  reported a quarterly
adjusted
loss of 8 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -6 cents.  The mean expectation of six analysts for the
quarter was for a loss of 9 cents per share. Wall Street
expected results to range from -11 cents to -8 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Trevi Therapeutics Inc's reported EPS for the quarter was
a loss
of 8 cents​.
    * The company reported a quarterly loss of $7.82 million.
    * Trevi Therapeutics Inc shares had risen by 158.2% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Trevi
Therapeutics Inc is $7.50 
This summary was machine generated from LSEG data March 20 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.09          -0.08          Beat
 Sep. 30 2023      -0.09          -0.08          Beat
 Jun. 30 2023      -0.08          -0.07          Beat
 Mar. 31 2023      -0.07          -0.06          Beat